Log In
BCIQ
Print this Print this
 

VAR 200

  Manage Alerts
Collapse Summary General Information
Company Variant Pharmaceuticals Inc.
DescriptionHydroxypropyl beta cyclodextrin
Molecular Target
Mechanism of Action 
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPreclinical
Standard IndicationNephropathy
Indication DetailsTreat focal segmental glomerulosclerosis (FSGS)
Regulatory Designation
PartnerL&F Research LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/18/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today